For families and patients wanting more information about Allo Phase 2 Alzheimer’s Clinical Trial: LEARN MORE

Troubled by hot flashes? Learn more about the HF Relief Study being conducted at the University of Arizona to test the effectiveness of a natural product, PhytoSERM, to alleviate hot flashes:

For information about the PhytoSERM Brain Clinical Trial: LEARN MORE

Our Researchers Develop Regenerative, Safe Therapeutic for Alzheimer’s Disease

University of Arizona researchers have developed a new therapy for Alzheimer’s disease designed to restore cognitive function in early-stage patients.

The team, led by Dr. Roberta Diaz Brinton, director of the Center for Innovation in Brain Science and a member of the BIO5 Institute, found that the neurosteroid allopregnanolone, or allo, used to treat women with postpartum depression, promotes connectivity between neural networks required for cognitive function by generating new neurons and synapses in patients in the early stages of Alzheimer’s disease. The therapy has been licensed to start-up NeuTherapeutics, Inc.

The Center for Innovation in Brain Science (CIBS) at the University of Arizona is addressing the challenge that, in the 21st century, there is not a single cure for a single neurodegenerative disease and is focused on four age-associated neurodegenerative diseases: Alzheimer’s, Parkinson’s, Multiple Sclerosis and ALS.

© 2024 Center for Innovation Brain Science. University of Arizona Health Sciences.

Skip to content